Gilead Sciences News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

23.10.20	Gilead Completes Transaction To Acquire Immunomedics - Quick Facts (RTTNews)
23.10.20	FDA OKs Gilead's Remdesivir As First COVID-19 Treatment Despite WHO Findings (RTTNews)
23.10.20	Pre-market Movers In Healthcare Sector: SAVA, KTOV, PRVL, IMMP, GILD, ITRM, BBI… (RTTNews)
22.10.20	FDA Approves Gilead's Antiviral Remdesivir For Treatment Of COVID-19 - Quick Facts (RTTNews)
21.10.20	Gilead: New Data Shows Biktarvy As Effective Treatment Regimen In Black Americans With HIV (RTTNews)
16.10.20	Kite: European CHMP Adopts Positive Opinion For KTE-X19 (RTTNews)
14.10.20	Gilead Says HSR Waiting Period For Immunomedics Tender Offer Expires - Quick Facts (RTTNews)
13.10.20	ATXI Plunges On Thumbs-down, VYGR's Huntington's Disease Trial On Hold, Deal Or No Deal For SURF? (RTTNews)
12.10.20	Gilead: Phase 2b/3 Trial Shows Efficacy Of Filgotinib - Quick Facts (RTTNews)
08.10.20	Gilead, European Commission Enter Joint Procurement Agreement For Remdesivir (RTTNews)
04.10.20	Trump Says 'real Test' Ahead In His COVID-19 Fight (RTTNews)
25.09.20	Gilead Sciences' Jyseleca Approved In Japan For Rheumatoid Arthritis Treatment (RTTNews)
24.09.20	Gilead Sciences To Settle Alleged False Claims Act (RTTNews)
15.09.20	MRNS Catches Eye, SAVA Soars On Alzheimer's Study, ETNB Abuzz Over NASH Trial, GILD Snaps Up IMMU (RTTNews)
14.09.20	Gilead Sciences To Buy Immunomedics In $21 Bln Deal (RTTNews)
03.09.20	Kite, HiFiBiO Join To Develop Antibodies Against Acute Myeloid Leukemia (RTTNews)
02.09.20	ATNX To Face FDA In Feb, ICPT Trims Workforce, JNCE Jumps On GILD Deal, SNY's Kevzara Flops Again (RTTNews)
01.09.20	Stock Alert: Jounce Therapeutics Surges 50% After Inking Oncology Deal With Gilead Sciences (RTTNews)
01.09.20	Gilead, Jounce Agree To License JTX-1811 Program (RTTNews)
19.08.20	Pre-market Movers In Healthcare Sector: NMTR, VRNA, AXDX, GLPG... (RTTNews)
19.08.20	ALBO Drops NASH Drug Development, FDA Says No To Filgotinib, SUPN On Watch, Vanda & ODYSSEY (RTTNews)
19.08.20	Gilead Gets CRL For Filgotinib For Moderately To Severely Active Rheumatoid Arthritis Treatment (RTTNews)
11.08.20	Gilead Sciences Says China NMPA Approves Truvada For HIV Pre-Exposure Prophylaxis (RTTNews)
10.08.20	Gilead Files NDA For Remdesivir For Treatment Of COVID-19 (RTTNews)
07.08.20	Pfizer Signs Deal To Boost Supply Of Gilead's Remdesivir For COVID-19 Patients (RTTNews)
30.07.20	Gilead Sciences Posts Q2 Loss, Lifts FY Outlook (RTTNews)
30.07.20	Gilead Sciences Inc. Q2 adjusted earnings of $1.11 per share (RTTNews)
25.07.20	FDA Approves Kite's Tecartus For Relapsed Or Refractory Mantle Cell Lymphoma Treatment (RTTNews)
24.07.20	Gilead: CHMP Adopts Positive Opinion For Jyseleca In Treatment Of Rheumatoid Arthritis (RTTNews)
21.07.20	Gilead To Acquire 49.9% Equity Interest In Tizona - Quick Facts (RTTNews)
10.07.20	Gilead's New Analysis On Remdesivir Shows Improved Clinical Recovery And Reduced Risk Of Death (RTTNews)
10.07.20	Australia Grants Provisional Approval For Gilead's Remdesivir To Treat COVID-19 (RTTNews)
06.07.20	Mylan: India Approves Remdesivir For Restricted Emergency Use In COVID-19 Patients (RTTNews)
03.07.20	EU Approves Gilead's Remdesivir To Treat COVID-19 (RTTNews)
02.07.20	U.S. Secures Most Of Remdesivir Supply Till September (RTTNews)
01.07.20	Gilead To Present New Data From Its HIV Research & Development Program - Quick Facts (RTTNews)
29.06.20	Gilead Prices Remdesivir At $390 Per Vial; 5-day Treatment To Cost $2,340 Per Patient (RTTNews)
23.06.20	Gilead Sciences To Acquire 49.9% Stake In Pionyr Immunotherapeutics For $275 Mln - Quick Facts (RTTNews)
23.06.20	MYOV To Report SPIRIT 1 Data, EVLO Joins COVID-19 Drug Race, NVTA Loosens Purse Strings (RTTNews)
22.06.20	Gilead To Trial Inhaled Version Of Remdesivir On Covid-19 Patients (RTTNews)
17.06.20	AstraZeneca's Potential Vaccine Likely To Protect Against Covid-19 For A Year : Report (RTTNews)
13.06.20	Dr. Reddy's Laboratories Enters Licensing Deal With Gilead Sciences For Remdesivir (RTTNews)
12.06.20	Kite To Manufacture CAR T Cell Therapies In Europe - Quick Facts (RTTNews)
10.06.20	Study: Remdesivir Prevented Lung Damage In Monkeys Infected With COVID-19 (RTTNews)
02.06.20	NTLA Gains On Amended REGN Deal, GILD Reports SIMPLE Results, MYOV On Watch, NVUS Slumps (RTTNews)
01.06.20	Stock Alert: Gilead Down 4% On Remdesivir Trial Data (RTTNews)
30.05.20	The Week That Was: MRK Enters COVID Space, GSK's 1Bln Dose Target, Roche, GILD Team Up For REMDACTA (RTTNews)
29.05.20	At The ASCO: ONCY, IMV, CRDF, GILD, TAK… (RTTNews)
28.05.20	Genentech Initiates Phase III Trial Of Actemra Plus Remdesivir On Severe COVID-19 Pneumonia (RTTNews)
28.05.20	PHAS To Begin COVID-19 Drug Trial In June, MRSN Hits New High, LJPC Plunges, RCUS On Watch (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Roche Hldg G	255.50	0.75 %	K V
Nestle	74.88	0.62 %	K V
CieFinRichemont	137.90	0.40 %	K V
Swiss Life Hldg	699.60	0.32 %	K V
Swisscom	504.50	0.30 %	K V
Sika	215.80	-0.37 %	K V
Givaudan	3’966.00	-0.40 %	K V
Lonza Grp	535.80	-0.41 %	K V
Geberit	514.60	-0.46 %	K V
ABB	49.07	-0.95 %	K V

mehr

31.12.24		Schwacher Handel: NASDAQ 100 beendet die Sitzung im Minus
31.12.24		Angespannte Stimmung in New York: Dow Jones liegt zum Handelsende im Minus
31.12.24		Dienstagshandel in New York: NASDAQ 100 leichter
31.12.24		NYSE-Handel Dow Jones zeigt sich am Dienstagnachmittag leichter
31.12.24		Dezember 2024: Analysten sehen Potenzial bei Novartis-Aktie
31.12.24		Analysten sehen für Roche-Aktie schwarz
31.12.24		Experten sehen bei Merck-Aktie Potenzial
31.12.24		Handel in New York: Dow Jones gibt am Mittag nach

31.12.24

Schwacher Handel: NASDAQ 100 beendet die Sitzung im Minus

31.12.24

Angespannte Stimmung in New York: Dow Jones liegt zum Handelsende im Minus

31.12.24

Dienstagshandel in New York: NASDAQ 100 leichter

31.12.24

NYSE-Handel Dow Jones zeigt sich am Dienstagnachmittag leichter

31.12.24

Dezember 2024: Analysten sehen Potenzial bei Novartis-Aktie

31.12.24

Analysten sehen für Roche-Aktie schwarz